Goebeler M - Search Results

1

Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification.

Höhn J, Krieghoff-Henning E, Jutzi TB, von Kalle C, Utikal JS, Meier F, Gellrich FF, Hobelsberger S, Hauschild A, Schlager JG, French L, Heinzerling L, Schlaak M, Ghoreschi K, Hilke FJ, Poch G, Kutzner H, Heppt MV, Haferkamp S, Sondermann W, Schadendorf D, Schilling B, Goebeler M, Hekler A, Fröhling S, Lipka DB, Kather JN, Krahl D, Ferrara G, Haggenmüller S, Brinker TJ. Höhn J, et al. Among authors: goebeler m. Eur J Cancer. 2021 May;149:94-101. doi: 10.1016/j.ejca.2021.02.032. Epub 2021 Apr 7. Eur J Cancer. 2021. PMID: 33838393 Free article.

2

Characterization of functional domains in the Merkel cell polyoma virus Large T antigen.

Houben R, Angermeyer S, Haferkamp S, Aue A, Goebeler M, Schrama D, Hesbacher S. Houben R, et al. Among authors: goebeler m. Int J Cancer. 2015 Mar 1;136(5):E290-300. doi: 10.1002/ijc.29200. Epub 2014 Sep 19. Int J Cancer. 2015. PMID: 25208506 Free article.

3

Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.

Zhu G, Yi X, Haferkamp S, Hesbacher S, Li C, Goebeler M, Gao T, Houben R, Schrama D. Zhu G, et al. Among authors: goebeler m. Cancer Lett. 2016 Jun 28;376(1):43-52. doi: 10.1016/j.canlet.2016.03.028. Epub 2016 Mar 18. Cancer Lett. 2016. PMID: 27000992

4

Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.

Thiem A, Kneitz H, Schummer P, Herz S, Schrama D, Houben R, Goebeler M, Schilling B, Gesierich A. Thiem A, et al. Among authors: goebeler m. Acta Derm Venereol. 2017 Nov 15;97(10):1252-1254. doi: 10.2340/00015555-2757. Acta Derm Venereol. 2017. PMID: 28761962 Free article. No abstract available.

5

Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma.

Haug V, Behle V, Benoit S, Kneitz H, Schilling B, Goebeler M, Gesierich A. Haug V, et al. Among authors: goebeler m. Br J Dermatol. 2018 Oct;179(4):993-994. doi: 10.1111/bjd.16780. Epub 2018 Jul 23. Br J Dermatol. 2018. PMID: 29758087 No abstract available.

6

Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors.

Thiem A, Schummer P, Ueberschaar S, Kerstan A, Kneitz H, Schrama D, Appenzeller S, Meierjohann S, Schilling B, Goebeler M, Gesierich A. Thiem A, et al. Among authors: goebeler m. Melanoma Res. 2018 Oct;28(5):465-468. doi: 10.1097/CMR.0000000000000458. Melanoma Res. 2018. PMID: 29781871

7

Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.

Milsch L, Gesierich A, Kreft S, Livingstone E, Zimmer L, Goebeler M, Schadendorf D, Schilling B. Milsch L, et al. Among authors: goebeler m. Eur J Cancer. 2018 Aug;99:58-65. doi: 10.1016/j.ejca.2018.05.012. Epub 2018 Jun 12. Eur J Cancer. 2018. PMID: 29906735

8

Nocardiosis in a patient with anti-PD-1-associated colitis treated with infliximab.

Glutsch V, Gesierich A, Goebeler M, Forster J, Schilling B. Glutsch V, et al. Among authors: goebeler m. Eur J Cancer. 2018 Sep;101:284-286. doi: 10.1016/j.ejca.2018.06.014. Epub 2018 Jul 13. Eur J Cancer. 2018. PMID: 30017385 No abstract available.

9

The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.

Appenzeller S, Gesierich A, Thiem A, Hufnagel A, Jessen C, Kneitz H, Regensburger M, Schmidt C, Zirkenbach V, Bischler T, Schilling B, Siedel C, Goebeler ME, Houben R, Schrama D, Gehrig A, Rost S, Maurus K, Bargou R, Rosenwald A, Schartl M, Goebeler M, Meierjohann S. Appenzeller S, et al. Among authors: goebeler m, goebeler me. Cancer. 2019 Feb 15;125(4):586-600. doi: 10.1002/cncr.31843. Epub 2018 Dec 18. Cancer. 2019. PMID: 30561760 Free article.

10

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.

Glutsch V, Grän F, Weber J, Gesierich A, Goebeler M, Schilling B. Glutsch V, et al. Among authors: goebeler m. J Immunother Cancer. 2019 Jul 12;7(1):181. doi: 10.1186/s40425-019-0655-4. J Immunother Cancer. 2019. PMID: 31300044 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

448 results

Search Page